Skip to content

Study · Non-randomized trial · n = 154 · 2024

3 results

Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.

Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, Turfanda I, Cox DA

Diabetes care1 Sept 2024Cited by 3 (Europe PMC)

PMID38954432 (opens in a new tab)DOI10.2337/dc24-0322 (opens in a new tab)PepBankPUB-38954432
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In youths with diabetes, dulaglutide decreased eGFR more than placebo.

    In plain wordsIn youths with diabetes, dulaglutide decreased estimated kidney filtration more than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseeGFR change
    Study

    n = 154

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    eGFR change
    −5.8 mL/min/1.73 m2
    dulaglutide
    eGFR change
    −0.1 mL/min/1.73 m2
    placebo

    Source sentences

    Summary
    Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (-5.8 vs. -0.1 mL/min/1.73 m2; P = 0.016).
    1 context sentence
    Summary · context
    Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In youths with diabetes, glomerular hyperfiltration prevalence decreased with dulaglutide but increased with placebo.

    In plain wordsIn youths with diabetes, excessive kidney filtration became less common with dulaglutide but more common with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlomerular hyperfiltration prevalence
    Study

    n = 154

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively).
    1 context sentence
    Summary · context
    Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.
  3. 03HumanNon-randomized trialEfficacy outcome

    In youths with diabetes, proteinuria prevalence decreased with dulaglutide but increased with placebo.

    In plain wordsIn youths with diabetes, protein in urine became less common with dulaglutide but more common with placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseProteinuria prevalence
    Study

    n = 154

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively).
    1 context sentence
    Summary · context
    Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.